Funded Apps Startups in Cambridge
Across the 10 most recent “Apps” funding entries in Cambridge listings, the largest disclosed round is Proof Diagnostics’ $45M Series A on 2022-04-07.
Across the 10 most recent “Apps” funding entries in Cambridge listings, the largest disclosed round is Proof Diagnostics’ $45M Series A on 2022-04-07. That top disclosed amount is followed by Solo.io’s $135M Series C in 2021-10-07, which is substantially higher than the rest of the disclosed rounds shown (other disclosed figures include Venly’s $13M on 2022-10-03, and several $4M rounds). Most of the capital cluster sits in a Cambridge (Massachusetts) concentration: 9 of 10 rows list Cambridge, Massachusetts, while the remaining row is Cambridge, United Kingdom (RapidX Bio, 2026-01-26).
The disclosed amounts also show a stage mix skewed toward mid-stage and early-stage together, while multiple rounds remain not publicly sized: 4 of 10 entries are “undisclosed” (RapidX Bio 2026-01-26; Tailbox 2023-06-05; Evaluate.Market 2022-08-05; plus one other undisclosed). Temporally, the span runs from 2021-01-20 (Orreco Series B) to 2026-01-26 (RapidX Bio), with the most recent cluster concentrated in late 2025 and early 2026 (Orreco 2025-12-15; Expected Parrot 2025-12-03; RapidX Bio 2026-01-26).
Most recent rounds
10 shownRelated listings
Frequently asked
What’s the largest disclosed round among these Cambridge “Apps” entries, and how does it compare with the next-largest disclosed amounts?
Solo.io’s $135M Series C on 2021-10-07 is the only disclosed round above $50M in the visible set; the next-largest disclosed is Proof Diagnostics’ $45M Series A on 2022-04-07. Other disclosed rounds sit below that level, including Venly’s $13M on 2022-10-03 and multiple $4M rounds (Cake 2021-07-21; Orreco 2021-01-20 and 2021-01-20-equivalent 2025-12-15 row).
Do the rounds cluster geographically around Cambridge, or are there meaningful splits between Cambridge, MA and Cambridge, UK?
Cambridge, Massachusetts dominates with 9 of 10 rows (e.g., Solo.io 2021-10-07; Proof Diagnostics 2022-04-07; Orreco 2025-12-15). The geographic outlier is RapidX Bio, Cambridge, United Kingdom, dated 2026-01-26, which is the only UK-based entry in this view.
Which entries fall in the most recent 90 days covered by the table, and what pattern do they show in disclosed sizing?
Within the latest 90-day window ending at 2026-01-26, the visible rows include RapidX Bio (2026-01-26, undisclosed), Orreco (2025-12-15, $4M), and Expected Parrot (2025-12-03, $500K). Two of the three latest entries have disclosed amounts ($4M and $500K), while RapidX Bio is not publicly sized (undisclosed).
Is there an obvious stage mix skew, or do early-stage and later-stage rounds both appear frequently?
Early-stage signals appear alongside later-stage: Seed is listed for Cake (2021-07-21, $4M) and Evaluate.Market (2022-08-05, undisclosed), while later-stage appears via Solo.io’s Series C (2021-10-07, $135M) and Proof Diagnostics’ Series A (2022-04-07, $45M). Convertible Note is also present (Venly, 2022-10-03, $13M), suggesting the stage mix spans more than one tranche rather than concentrating in a single phase.
Are there outliers in disclosed amounts or “unknown/undisclosed” reporting worth flagging?
Two disclosure outliers stand out: Solo.io’s $135M (2021-10-07) materially exceeds all other disclosed amounts shown, while several entries provide no disclosed figure (RapidX Bio 2026-01-26; Tailbox 2023-06-05; Evaluate.Market 2022-08-05, all “undisclosed”). On the low end, Expected Parrot’s $500K (2025-12-03) sits well below the cluster of $4M rounds (Cake and Orreco entries, each showing $4M).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.